Emulating on the successful Viral Vector Process Development Summit in Boston, this summit was excited to connect thought leaders in CMC, Regulatory, Upstream and Downstream Processing in Europe this summer and address the unique challenges in this emerging market.

The Viral Vector Formulation & Process Development Summit Europe was the meeting that  approached the most prominent challenges in the context of viral vector-based vaccine, gene and cell therapy process development in Europe.

Across 2 days, this summit helped attendees to benchmark their formulation, process development and understand reference materials against the most common vector candidates, navigate through the fast-evolving regulatory landscape and achieve a seamless scale-up.

They heard first-hand experience from the likes of Roche, VectorY, UCB, Boehringer Ingelheim and AviadoBio and many more to avoid common pitfalls:

• 2 main conference days packed with 14+ case studies with technical updates and 3 roundtable discussions to spark innovations and conversation
• 3 and a half hours of networking opportunities to interact with industry thought leaders and build meaningful relationships

This was a unique forum dedicated to viral vector process development professionals in Europe so clear 2 days of your agenda and be part of the conversation in 2024.